|
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) |
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) ÀλçºÎ¹® 10³âÀÌ»ó °æ·ÂÀÚ ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Àλç/ÀÎÀç°³¹ß/ä¿ë/±³À° |
10³â¡è |
ä¿ë½Ã |
11.30 |
|
|
±ÙÈÁ¦¾à |
±ÙÈÁ¦¾à(ÁÖ) RAä¿ë
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
10³â¡è |
»ó½Ãä¿ë |
11.21 |
|
|
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) |
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) ÅëÁõºÐ¾ß ¸¶ÄÉÆà °æ·Â ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
10³â¡è |
ä¿ë½Ã |
11.20 |
|
|
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) |
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) ȸ°èºÎ¹® (°æ·Â) ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
8³â¡è |
ä¿ë½Ã |
12.01 |
|
|
(ÁÖ)¼¼Á¾¸Þµñ½º |
Á¦¾à¿µ¾÷ ¼¿ïÁöÁ¡¸Å´ÏÀú
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
8³â¡è |
ä¿ë½Ã |
04.09 |
|
|
ºñº¸Á¸ |
ȸ°è/À繫 °æ·ÂÁ÷¿ø ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
8³â¡è |
ä¿ë½Ã |
12.07 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA II (Regional Lead Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
03.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Medical Advisor, Liver Disease (Metaboli
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
6³â¡è |
ä¿ë½Ã |
12.15 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
07.21 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
05.04 |
|
|
À£¸¶Ä¿¹ÙÀÌ¿À |
À£¸¶Ä¿¹ÙÀÌ¿À ½Å±ÔÇ×¾ÏÁ¦ ±âÀü¿¬±¸¿ø
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
08.12 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Regulatory Officer / Senior Regulatory O
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
05.04 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
08.18 |
|
|
(ÁÖ)¿À·¡¿Â¶óÀÌÇÁ»çÀ̾𽺠|
[Á¤±ÔÁ÷] B2B ¿µ¾÷ °æ·Â ä¿ë
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
11.29 |
|